Business
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Offic
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Nataliya Agafonova","length":18,"tagName":"p"},{"type":"image","alt":"Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron","displaySize":"","headline":null,"caption":"Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":109,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/025b5ef53f21da23bcd9028e2d842f1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D0k9wSAfkbUqGepOFlp68A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/025b5ef53f21da23bcd9028e2d842f1a","width":109,"height":119}}},{"type":"text","content":"Joshua Hare","length":11,"tagName":"p"},{"type":"image","alt":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","displaySize":"","headline":null,"caption":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":109,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GiloV_.I1LiY.7J9ReDotg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8","width":109,"height":119}}},{"type":"text","content":"MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak on multiple panel discussions at the Glob...